Publication | Open Access

Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment

VaccinationLymphoid NeoplasiaImmunodeficienciesImmunologySeropositive ResponseImmunodominanceTherapeutic VaccineVaccine EfficacyNon-hodgkin Lymphoma PatientsImmunotherapyMedicineCovid-19Anti-cd20 Monoclonal Antibodies